AGP Picks
View all

AGP Executive Report

Last update: 10 hours ago

Hepatitis B Trial: Danish researchers are defending a controversial proposed study in Guinea-Bissau that would delay the hepatitis B birth-dose vaccine for half of 14,000 newborns until six weeks of age. The revised protocol has reportedly received ethics approvals, but Health Minister Quinhin Nantote says the government has not authorized the trial. The vaccine has been used safely for decades, and WHO recommends giving it within 24 hours of birth; the study’s disputed status has renewed concerns about infant protection and research oversight.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

fallback image
Oct. 15, 2026

Stand Up for Science publishes Guinea-Bissau vaccine trial investigation

AGP

fallback image
Oct. 13, 2026

Stand Up for Science pushes Congress to halt CDC vaccine study in Guinea-Bissau

AGP

fallback image
Oct. 8, 2026

Stand Up for Science blasts CDC plan to revive Guinea-Bissau vaccine study

AGP


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate Press Release Service
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Press Release Service
Hepatitis B Guinea-Bissau trial: Researchers behind controversial study weigh in as confusion reigns over its fate

Hepatitis B Guinea-Bissau trial: Researchers behind controversial study weigh in as confusion reigns over its fate

Guinea-Bissau Has Not Approved Hep B Vaccine Trial in Newborns

Guinea-Bissau Has Not Approved Hep B Vaccine Trial in Newborns


fallback image
Oct. 15, 2026

As CDC Renews Controversial Guinea-Bissau Vaccine Trial, Stand Up for Science Makes Its Field Investigation Public

EIN Presswire

fallback image
Oct. 8, 2026

Stand Up for Science Condemns CDC’s Attempts to Restart Controversial Vaccine Study in Guinea-Bissau

EIN Presswire

fallback image
Oct. 13, 2026

Stand Up for Science Launches Petition to Halt CDC Vaccine Study in West Africa

EIN Presswire

fallback image
Feb. 22, 2026

Guinea-Bissau Stops Trump-Backed Hepatitis B Vaccine Study

MENAFN

fallback image
Feb. 22, 2026

Guinea-Bissau Stops US-Funded Hepatitis B Vaccine Trial

MENAFN

fallback image
Oct. 12, 2026

Countries locked into IMF austerity programs are also around twice as vulnerable to economic fallout from war against Iran

Oxfam

More press releases

Video Stories

YouTube video thumbnail:  IMF Raises Africa Growth Outlook, Warns of Shrinking aid
Play
IMF Raises Africa Growth Outlook, Warns of Shrinking aid
YouTube video thumbnail:  Cameroon’s Anglophone Crisis: The Cost to Ordinary People
Play
Cameroon’s Anglophone Crisis: The Cost to Ordinary People
Affinity Group Publishing Logo Showcase
Discover Affinity Group Publishing
YouTube video thumbnail:  Spring-Summer 2027 Ready-to-Wear Collections: Africa in the Spotlight at Paris Fashion Week
Play
Spring-Summer 2027 Ready-to-Wear Collections: Africa in the Spotlight at Paris Fashion Week
YouTube video thumbnail: Kinshasa Braces for Potential Conflict as Kabila Joins M23
Play
Kinshasa Braces for Potential Conflict as Kabila Joins M23

Video Title

Sign up for:

Guinea Bissau Health Bulletin

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Guinea Bissau Health Bulletin

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.